Plain-English summaries of the pivotal GLP-1 trials. Outcomes, populations, durations.
Pivotal trial of semaglutide 2.4 mg weekly for chronic weight management in adults without diabetes.
Semaglutide 2.4 mg in adults with overweight/obesity AND type 2 diabetes.
Semaglutide combined with intensive behavioral intervention.
What happens when patients stop semaglutide after run-in.
Two-year semaglutide treatment.
Semaglutide in adults with obesity-related HFpEF.
Cardiovascular outcomes in non-diabetic adults with established CVD.
Pivotal trial of tirzepatide for chronic weight management without diabetes.
Tirzepatide in adults with overweight/obesity AND T2D.
Tirzepatide initiated after lifestyle intervention.
Tirzepatide in adults with obesity and moderate-severe OSA.
Semaglutide and progression of kidney disease in T2D.
Five minutes. Free. No pressure.